Navigation Links
Dyadic Demonstrates Industry-leading Biofuels Enzyme Performance
Date:7/16/2012

JUPITER, Fla., July 16, 2012 /PRNewswire/ -- Dyadic International, Inc. ("Dyadic") (OTC Pink: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries, today unveiled its latest biofuels enzyme advancement, AlternaFuel® CMAX3™. This next generation product enables the production of cellulosic biofuels and bio-based chemicals from a wide range of renewable non-food feedstocks under broad operating conditions.

(Logo:  http://photos.prnewswire.com/prnh/20110621/CL06708LOGO )

Dyadic's President and CEO, Mark Emalfarb, stated, "The data supporting this product clearly demonstrates Dyadic's scientific capabilities to leverage our C1 technology platform to create enzyme mixtures whose performance rivals the leading biofuels enzyme product on the market. This is largely due to the inherent robustness and versatility of the C1 genome and expression system, both of which have considerable untapped potential. The results obtained with AlternaFuel® CMAX3™ are not only relevant for the production of biofuels but also for bio-based chemicals and biogas. Dyadic and its licensees are continuing to develop better performing enzymes to further reduce the total cost of producing advanced biofuels and other bio-based products."

Jan Wery, Science Director at Dyadic Netherlands, added, "AlternaFuel® CMAX3™ achieved a similar saccharification yield at pH 5.0 and substantially better results at pH 6.0 than those achieved by the current leading competitive biofuels enzyme product. Saccharification yield is defined as the relative amount of fermentable sugars released through enzymatic hydrolysis from lignocellulosic biomass such as agricultural feedstock and waste. This important parameter demonstrates the level of progress being made across the entire industrial enzyme industry in developing enzymes necessary for lignocellulosic biomass to replace petroleum in fuel and chemical production."

About AlternaFuel® CMAX3™

AlternaFuel® CMAX3™ is the latest generation of a cellulase and hemicellulase complex based on Dyadic's C1 platform technology which enables efficient conversion of multiple forms of non-food biomass into fermentable sugars at broad pH and temperature ranges that can be used to produce biofuels, bio-based chemicals, biogas and other bio-based products.

For more information on AlternaFuel® CMAX3™, please visit Dyadic's recently remodeled website at www.dyadic.com.

About Dyadic

Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary C1 fungal production platform and other technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzymes and others proteins for the bioenergy, industrial enzyme and biopharmaceutical industries. 

Dyadic actively pursues licensing arrangements and other commercial opportunities to leverage the value of these technologies by providing its partners and collaborators with the benefits of manufacturing and/or utilizing the proteins which these technologies help produce.

Dyadic Netherlands is a wholly owned subsidiary of Dyadic based in Wageningen, The Netherlands that conducts research and development activities for the benefit of Dyadic, its collaborators and customers.  Please visit Dyadic Netherland's website at www.dyadic.nl.

Cautionary Statement for Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, Dyadic expressly disclaims any intent or obligation to update any forward-looking statements.


'/>"/>
SOURCE Dyadic International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Dyadic International To Release First Quarter 2012 Financial Results And Host Conference Call
2. Dyadic International Launches FibreZyme® G5000 High Performance Powder Pulp and Paper Enzyme in Booth #1065 at Tissue World Americas Conference
3. Dyadic International Partners with Leading Provider of Nutritional Ingredient Solutions for Production of Food Enzymes
4. Hark! Group demonstrates first heralded single photon source made from silicon
5. New England Biolabs Demonstrates Support for Interactive Scientific Literature by Collaborating with AQnowledge
6. Nitor Group Demonstrates Direct Product Suite at Direct Implementation and Adoption Summit May 31-June 1
7. OrbusNeichs Combo Dual Therapy Stent™ Demonstrates Favorable Clinical and Safety Outcomes at 12-Month Follow-Up
8. Entinostat Demonstrates Activity in Hodgkins Lymphoma
9. Post Heart Attack Recovery Not Aided By Stem Cell Injections, But Trial Demonstrates Promise
10. AtheroNova Inc. Preclinical Study Demonstrates 95% Reduction in Arterial Plaque Formation
11. NKTR-102 Demonstrates Synergistic Anti-Tumor Activity in Combination with Pegylated Liposomal Doxorubicin in Platinum-Resistant Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... In today,s pre-market research, Stock-Callers.com ... Biotech industry: Sangamo Therapeutics Inc. (NASDAQ: SGMO), Eyegate Pharmaceuticals ... and Regulus Therapeutics Inc. (NASDAQ: RGLS ). ... its rating on Pharmaceuticals/Biotechnology to "Overweight" from "Market Weight." Learn more ... ...
(Date:3/22/2017)... March 22, 2017  Ascendis Pharma A/S (Nasdaq: ... TransCon technology to address significant unmet medical needs ... the full year ended December 31, 2016. ... our company as we broadened our pipeline and ... rare disease company with an initial focus on ...
(Date:3/22/2017)...   iSpecimen ®, the marketplace for ... Service (DPS), a full-service anatomic pathology reference lab ... States , has joined a program offered by ... (DHIN) to make human biospecimens and associated data available ... announced in 2015 as a collaboration between iSpecimen and ...
(Date:3/22/2017)... 2017   Boston Biomedical , an industry leader ... target cancer stemness pathways, today announced its Board of ... Chief Executive Officer, effective April 24, 2017. ... , M.D., FACP, who has led Boston Biomedical since ... leadership, Boston Biomedical has grown from a "garage startup" ...
Breaking Biology Technology:
(Date:3/2/2017)... Australia , March 2, 2017 Australian ... Ltd (ASX: CYP), has signed an agreement with ... from the Monash Biomedicine Discovery Institute and Department of ... to conduct a further preclinical study to support the ... treatment of asthma.  Asthma is a ...
(Date:2/28/2017)... 2017 News solutions for biometrics, bag drop ... ... 14 to 16 March, Materna will present its complete end-to-end ... travel is a real benefit for passengers. To accelerate the ... passenger touch point solutions to take passengers through the complete ...
(Date:2/26/2017)... 2017  Securus Technologies, a leading provider of ... safety, investigation, corrections and monitoring, announces the appointment ... "Too often, too many offenders return to ... are trying to tackle this ongoing problem and ... family members. While significant steps are underway, Securus continues ...
Breaking Biology News(10 mins):